All News

ANCA, vasculitis, test

Updated AAV Treatment Recommendations

EurekAlert!

AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). This variety can make management challenging.

Read Article
obesity.knee_.arthritis.jpg

Metformin Reduces Osteoarthritis Risk

MedPage Today

Metformin may help cut the risk of osteoarthritis (OA) in those with type 2 diabetes, researchers reported.

Read Article
guidelines.recommendations.jpg

2022 EULAR Recommendations for ANCA-associated Vasculitis

Jack Cush, MD

EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Read Article
Pills_0.jpg

Polypharmacy Increased in Psoriatic Arthritis

Jack Cush, MD

Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA.

Read Article
DLE discoid lupus

A Pilot Trial of Anifrolumab in Discoid Lupus

Jack Cush, MD

A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE). 

Read Article
immune.activity.cytokine.jpg

Itaconate - A Potential New Immunosuppressive

EurekAlert!

Researchers have revealed the modulatory effect of the anti-inflammatory metabolite itaconate (ITA) on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases.

Read Article
DMARDs,biologics,RA

Cost-Effective Use of Biological and Targeted Synthetic DMARDs

Jack Cush, MD

An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).

Read Article
joint.wrist_.pain_.CTS_.Carpal.jpg

Carpal Tunnel - Steroid injection vs. Night Splinting

Jack Cush, MD

A prospective, pragmatic, open-label, randomized trial conducted by the UK National Health Service, studied interventions in patients with carpal tunnel syndrome (CTS) and found no advantage to either CTS corticosteroid injection (CSI) or night splinting (NS) as the initial treatment of CTS.

Read Article
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2023 Year in Review COMPLETE-PsA: DMARDs for PsA! LEF+MTX better than MTX alone, 78 total patients PASDAS at week 16: 59% for MTX+LEF vs 34% MTX+PBO More treatment discontinuations (10 vs 3) in combo group due to GI intolerance @RheumNow https://t.co/3Al8PQmNli
Eric Dein ericdeinmd ( View Tweet)
#ClinicalPearl #Methotrexate weekly May reduce side effects in rapidly dividing cells vs using it daily or every few days. GI, oral, bone marrow side effects should be less if once a week. Joel Kremer ⁦@RheumNow⁩ #RNL2023 https://t.co/i0LZoQuK0w
Janet Pope Janetbirdope ( View Tweet)
Tremendously emotional (and unfiltered) first person account of his fight with COVID-19 by Miracle Larry who thanked our Dr. Cush @RheumNow for his ingenuity in fighting COVID-19, thanking healthcare workers for all they do, and reminding us to be empathic. #RNL2023 https://t.co/i0D7r8dR8n
Robert B Chao, MD doctorRBC ( View Tweet)
RBC MTX polyglutamate levels may be the “truth serum” for those pts stating they are taking their MTX but you question it. Dr. Kremer @RheumNow #RNL2023

Dr. Rachel Tate uptoTate ( View Tweet)

Dr. Carol Langford on GPA treatment Duration of remission maintenance therapy? - at least 2 years, after 2 years, maintenance appropriate in many cases - consider RTX, and other cDMARDs (MTX, MMF, AZA) @RheumNow #RNL2023 https://t.co/VmswcnzN5v
Robert B Chao, MD doctorRBC ( View Tweet)
Is there role for MTX in GCA Favorable results in a meta-analysis with NNT 11 to prevent 1 cranial relapse BUT: limitations of meta-analysis, short follow-up, dose response not evaluated Robert Spiera at #RNL2023 @RheumNow https://t.co/sHx2ceVmAi
Eric Dein ericdeinmd ( View Tweet)
DMARDs/TNF for PMR: MTX- initial benefit, but no 5 year steroid sparing effect Infliximab - no benefit Lef - some benefit in case series Robert Spiera #RNL2023 @RheumNow https://t.co/cmwGEWHQEO
Eric Dein ericdeinmd ( View Tweet)
MTX as a treatment of OA, by Dr.Conaghan #RNL2023 ⁦@RheumNow⁩ Systemic inflammation might also be a part of OA?! https://t.co/grxMKtRLhj
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Conaghan shares unpublished data from PROMOTE study at #RNL2023 Early data shows MTX benefits pain in patients w/ OA, particularly more metabolically active. Looking forward to more data on this - though many many many DMARD trials thus far have been disappointing in OA @RheumNow https://t.co/Ieagp8mq31
Eric Dein ericdeinmd ( View Tweet)
Cost-Effective Use of Biological and Targeted Synthetic DMARDs An international task force of experts have developed evidence-based points to consider regarding the cost-effective use of b/tsDMARDs in the treatment of inflammatory rheumatic diseases. https://t.co/jpxQggd89T https://t.co/zjer5QTN3C

Links:

Dr. John Cush RheumNow ( View Tweet)
Does Methotrexate Work in Alopecia Universalis? Alopecia areata totalis (AT) and universalis (AU) are the most severe and difficult to treat forms of alopecia areata (AA). https://t.co/Lvd7P6r85w https://t.co/hX3rz5fBKT

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×